

GSK in Belgium

Who are we?

We are a global biopharma company with a purpose to **unite science, technology and talent to get ahead of disease together**.

We aim to positively impact the health of **2.5 billion people** by the end of the decade, as a successful, growing company where people can thrive.



Belgium: the heart of our vaccines

We have 3 important vaccines sites in Belgium.

Our infrastructure represents **the largest, integrated industrial network of vaccines**, from early discovery, through development, all manufacturing steps and export.



Wavre – This site is the heart of our vaccines business. It is **the largest vaccine production site in the world**, equivalent to

70 football fields.

Our colleagues responsible for the distribution of our vaccines and medicines in Belgium and in Luxembourg are also located in Wavre.

Our vaccines are exported to >160 countries.

We are the largest Walloon exporter: our vaccines account for 7.5% of exports.


70% of manufacturing time is dedicated to quality controls.



What we do

We prevent and treat disease with specialty medicines, vaccines and general medicines.

We focus on the science of the immune system and the use of new platform and data technologies, investing in four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; infectious diseases.



Our collaborators in Belgium

Our **Rixensart**, **Wavre** and **Gembloux** sites count **9,000** collaborators, including more than 2,000 scientific researchers from 85 countries..

20%
workers.

35%
employees.

45%
managers.

Our sustainable development strategy

A healthy planet for healthy people.

To support GSK's vision, we focus on 4 areas in Belgium: **Climate**, **Water**, **Waste** and **Biodiversity**.

To help get ahead of disease and deliver real human health impact we need to look broadly and deeply at the interconnections of climate, nature and health.

We're committed to a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045.



Our commitment to Global Health

We are investing over €1.2 billion over ten years to accelerate global health R&D, focusing on new medicines and vaccines to prevent and treat high burden infectious diseases.


We have always been **top of the Access to Medicine Index** since its creation.

Every minute, a child dies of malaria in Sub-Saharan Africa. Our malaria vaccine is the 1st vaccine approved worldwide. Meanwhile 10 countries have already implemented the vaccine in their vaccination programme. It was developed in Rixensart, and is currently manufactured there.

GSK is one of the main suppliers of vaccines for

unicef 

Gavi 
The Vaccine Alliance



Rixensart – This historic site houses our largest vaccine research and development (R&D) unit. The names of most of our vaccines developed here end with **–RIX**.

We have built here a unique international expertise, globally recognised, in the field of preclinical and clinical research.

17

candidate vaccines in research & development as well as 20 scientific collaborations with Belgian universities and research centres every year.

40

clinical trials in 2024 in Belgium, involving more than a thousand study participants.

€1.46

billion invested in vaccine R&D in 2024 as from Belgium.

Gembloux – New, unique, ultra-modern centre dedicated to the storage and export of our vaccines.



Ahead together

Want to find out more?

 be.gsk.com

The GSK logo is displayed in a bold, sans-serif font. The letters 'G' and 'S' are a darker orange, while the 'K' is a lighter, more vibrant orange. The letters are closely spaced and have a slight shadow effect.

External Communication and Public Affairs:

Elisabeth Van Damme | elisabeth.evandamme@gsk.com | +32 (0)478 27 26 41

GSK Vaccines | Avenue Fleming 20 – 1300 Wavre, Belgium

©GSK May 2025

Design: visible.be (26223)

Printed on FSC certified paper

CREDIT MIX SGSCH-COC-006801